Navigation Links
Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Date:9/25/2007

- Data Sufficient to Advance Product to Pivotal Phase -

WALTHAM, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC Bulletin Board: ABOS), today provided its clinical trial strategy for the SEPET(TM) Liver Assist Device including information regarding a pre-pivotal phase meeting with the US Food and Drug Administration (FDA). In a meeting held between Arbios and the FDA's Office for Device Evaluation and Research (ODE), the FDA indicated that, pending receipt of a final report, SEPET(TM) has met the required feasibility trial objectives and Arbios may advance its clinical development program to the pivotal phase. In response to the presentation of a pivotal trial design, the FDA provided the Company with comment and further indicated that a single pivotal study may be acceptable to the FDA, subject to a submission of a full clinical protocol to include additional information required in an Investigational Device Exemption (IDE) application. Arbios intends to file this information for review in the coming weeks, as a potential final step toward FDA authorization of a pivotal clinical trial for SEPET(TM).

"We are pleased with the discussion at our recent meeting with the FDA regarding our SEPET(TM) Liver Assist Device," commented Shawn Cain, Interim President and Chief Executive Officer of Arbios. "Following the results of our feasibility clinical trial, the FDA review group said that SEPET(TM) could advance into a multicenter pivotal clinical trial. We appear to be on track for near-term initiation of a pivotal registration trial of SEPET(TM) in the US."

We expect the proposed pivotal clinical trial would enroll 80 patients in the principal randomized, controlled phase of the study, targeted to achieve the primary endpoint of the trial, which is a clinically significant reduction in hepatic encephalopathy. Patients receiving SEPET(TM) treatment plus standard medical care would be compared to control patients receiving
'/>"/>

SOURCE Arbios Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- Commonwealth Cornerstone Group (CCG) today announced the completion of an ... help fund the expansion and consolidation of healthcare services provided ... . PHN is the largest federally qualified ... is the largest employer in Sharon,s ... Currently, PHN Sharon offers scattered services out of ...
(Date:12/24/2014)... 24, 2014 Kinex Pharmaceuticals announced today that ... Roswell Park Cancer Institute. KX2-361 (KX02), a ... has shown potent inhibitory activity against a broad panel ... resistant to Temozolomide (T98G), the most widely used chemotherapy ... brain tumor mouse model, KX2-361 consistently clears brain tumors ...
(Date:12/24/2014)... Trade Commission (ITC) issued its final decision in the case ... issued on December 23, the ITC ruled in favor of ... invalid. BMC President, James Xu called ... the ITC,s decision in this case. This victory for us ... beginning on the key patents in the case. ResMed chose ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... R1626 into phase IIb study, called POLI 1 ... of Roche,s new,investigational drugs for chronic hepatitis C ... given in combination with,PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) ... Association for the Study of the,Liver Disease (AASLD) ...
... MCLEAN, Va., Nov. 1 Science,Applications International Corporation ... awarded a contract extension by the National Institute ... and Infectious,Diseases (DMID), part of the National Institutes ... services. The seven-year cost-plus-fixed-fee contract has an ...
Cached Medicine Technology:Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 2Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 3Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 4Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 5Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 6Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 7SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases 2
(Date:12/26/2014)... (PRWEB) December 26, 2014 The Biofeedback ... place March 24-28, 2015 in Rome, Italy and is ... includes workshops on a wide variety of ... well as peak performance training in athletes. The scientific ... the world. , Biofeedback monitoring allows clients to see ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on ... Pennsylvania for 2014. The awards program, created in 2000, ... kind in the country. The program is a public/private ... Community and Economic Development, the Pennsylvania State Council of ... Penn Business Journal. , Charlie Wilson, Vice ...
(Date:12/25/2014)... December 26, 2014 This is a ... the global Sterilizers industry with a focus on the ... market status of the Sterilizers manufacturers and is a ... individuals interested in the industry. This report provides a ... and manufacturing technology. In this part, the report presents ...
(Date:12/25/2014)... 25, 2014 Product liability lawsuits filed ... recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in ... Order issued in the U.S. District Court, Northern District ... an open conference on January 7, 2015, at the ... in West Palm Beach, Florida. The Conference is scheduled ...
(Date:12/25/2014)... The short film “Color of Honor” by young director/producer ... true 9/11 hero, Welles Remy Crowther. It has been chosen ... of Nuremberg International Short Film Festival and the 8th International ... and director Luciana Lagana plays the mother of the ... Gregory Graham - Graham plays a heroic policeman ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... Says NCPA Study, DALLAS, Sept. 27 The ... so rapidly that these benefits,are now the fastest rising ... the rate of retirement benefits, according to a new,analysis ... a separate,study also released today, the NCPA says Chile,s ...
... gene variants that convey risk for schizophrenia affect apparently healthy ... may have different versions of these genes, called alleles. ... end up with schizophrenia, this does not mean they are ... the largest study of its kind to date, scheduled for ...
... Paramount Acquisition,Corp. (OTC Bulletin Board: PMQC, PMQCU, ... the filing of a third,amendment to the preliminary ... that was originally filed on June 18, 2007. ... meeting of,stockholders to be held to consider the ...
... Calif., Sept. 27 With cold and flu,season ... infants and toddlers,will soon be visiting their family ... most cases, children suffering from ear infections,are prescribed ... infection,but when antibiotics fail to stop ear infections ...
... to women worried about whether getting pregnant after cancer ... by Norwegian scientists, presented today (Thursday) at the European ... almost all types of cancer, the survival of women ... after being treated for the disease is no different ...
... NEWBERG, Ore., Sept. 27 A team of internationally,recognized ... spa,that will open in the spring of 2009 along ... northeast Newberg. Joan Austin, president of Springbrook Properties, ... Beach, Fla., will oversee,development of what is destined to ...
Cached Medicine News:Health News:Disability System Sorely in Need of Reform 2Health News:Disability System Sorely in Need of Reform 3Health News:Schizophrenia candidate genes affect even healthy individuals 2Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 2Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 3Health News:Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx 4Health News:Antibiotics Not Always Best Bet for Battling Childhood Ear Infections 2Health News:Study indicates pregnancy does not harm chances of survival from cancer 2Health News:International Consulting Firm Health Fitness Dynamics Hired to Oversee Springbrook Inn's Planned New Spa 2Health News:International Consulting Firm Health Fitness Dynamics Hired to Oversee Springbrook Inn's Planned New Spa 3
... The TOPCON ALE-3600 and ... assure perfectly fit lenses ... and with the convenience ... These lens edgers are ...
Inquire...
... have two choices for finishing. The first choice ... wholesale lab, which meant longer delay to deliver ... order in house, but that meant a substantial ... inventory, more space and employee training. TOPscan Remote ...
... Ergonomic, computer-integrated, flexibility, combined with the ... contemporary styling, make the new Topcon ... highly competitive 21st Century practice environments: ... lane fits comfortably in an 8' ...
Medicine Products: